Literature DB >> 15374887

Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function.

Wayne R Godfrey1, Darrin J Spoden, Ying G Ge, Seth R Baker, Baoling Liu, Bruce L Levine, Carl H June, Bruce R Blazar, Stephen B Porter.   

Abstract

CD4(+)CD25+ T regulatory (Treg) cells have been shown to critically regulate self and allograft tolerance in mice. Studies of human Treg cells have been hindered by low numbers present in peripheral blood and difficult purification. We found that cord blood was a superior source for Treg-cell isolation and cell line generation compared with adult blood. Cord blood CD4(+)CD25+ cells were readily purified and generated cell lines that consistently exhibited potent suppressor activity, with more than 95% suppression of allogeneic mixed lymphocyte reactions (MLRs) (29 of 30 donors). Cultured Treg cells blocked cytokine accumulation in MLRs, with a less robust inhibition of chemokine production. These cell lines uniformly expressed CD25, CD62L, CCR7, CD27, and intracellular cytotoxic T-lymphocyte antigen-4 (CTLA4). FoxP3 protein, but not mRNA, was specifically expressed. Upon restimulation with anti-CD3/CD28 beads, the cultured Treg cells produced minimal cytokines (interleukin-2 [IL-2], interferon-gamma [IFN-gamma], and IL-10) and preferentially expressed tumor growth factor-beta (TGF-beta) latency associated protein. Cytokine production, however, was restored to normal levels by restimulation with phorbol myristate acetate (PMA)/ionomycin. Cord blood-derived cultured suppressor cell function was predominantly independent of IL-10 and TGF-beta. These results demonstrate cord blood contains a significant number of Treg precursor cells capable of potent suppressor function after culture activation. Banked cord blood specimens may serve as a readily available source of Treg cells for immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15374887     DOI: 10.1182/blood-2004-06-2467

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  105 in total

Review 1.  Umbilical cord blood immunology: relevance to stem cell transplantation.

Authors:  Syh-Jae Lin; Dah-Chin Yan; Yen-Chang Lee; Hsiu-Shan Hsiao; Pei-Tzu Lee; Yu-Wen Liang; Ming-Ling Kuo
Journal:  Clin Rev Allergy Immunol       Date:  2012-02       Impact factor: 8.667

Review 2.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Authors:  Anandharaman Veerapathran; Joseph Pidala; Francisca Beato; Xue-Zhong Yu; Claudio Anasetti
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

4.  99th Dahlem conference on infection, inflammation and chronic inflammatory disorders: neonatal immune function and vaccine responses in children born in low-income versus high-income countries.

Authors:  A H J van den Biggelaar; P G Holt
Journal:  Clin Exp Immunol       Date:  2010-04       Impact factor: 4.330

5.  Immune-based approaches to the prevention of mother-to-child transmission of HIV-1: active and passive immunization.

Authors:  Barb Lohman-Payne; Jennifer Slyker; Sarah L Rowland-Jones
Journal:  Clin Perinatol       Date:  2010-12       Impact factor: 3.430

Review 6.  Immune regulatory cells in umbilical cord blood and their potential roles in transplantation tolerance.

Authors:  Young-June Kim; Hal E Broxmeyer
Journal:  Crit Rev Oncol Hematol       Date:  2010-08-19       Impact factor: 6.312

7.  Protein kinase C-theta mediates negative feedback on regulatory T cell function.

Authors:  Alexandra Zanin-Zhorov; Yi Ding; Sudha Kumari; Mukundan Attur; Keli L Hippen; Maryanne Brown; Bruce R Blazar; Steven B Abramson; Juan J Lafaille; Michael L Dustin
Journal:  Science       Date:  2010-03-25       Impact factor: 47.728

8.  In vivo expansion of CD4CD45RO-CD25 T cells expressing foxP3 in IL-2-treated HIV-infected patients.

Authors:  Irini Sereti; Hiromi Imamichi; Ven Natarajan; Tomozumi Imamichi; Meena S Ramchandani; Yunden Badralmaa; Steve C Berg; Julia A Metcalf; Barbara K Hahn; Jean M Shen; April Powers; Richard T Davey; Joseph A Kovacs; Ethan M Shevach; H Clifford Lane
Journal:  J Clin Invest       Date:  2005-06-02       Impact factor: 14.808

Review 9.  Production Assistance for Cellular Therapies (PACT): four-year experience from the United States National Heart, Lung, and Blood Institute (NHLBI) contract research program in cell and tissue therapies.

Authors:  William Reed; Stephen J Noga; Adrian P Gee; Cliona M Rooney; John E Wagner; Jeffrey McCullough; David H McKenna; Theresa L Whiteside; Albert D Donnenberg; Acacia K Baker; Robert W Lindblad; Elizabeth L Wagner; Traci Heath Mondoro
Journal:  Transfusion       Date:  2008-12-23       Impact factor: 3.157

10.  Selective expression of latency-associated peptide (LAP) and IL-1 receptor type I/II (CD121a/CD121b) on activated human FOXP3+ regulatory T cells allows for their purification from expansion cultures.

Authors:  Dat Q Tran; John Andersson; Donna Hardwick; Lolita Bebris; Gabor G Illei; Ethan M Shevach
Journal:  Blood       Date:  2009-03-18       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.